Argatroban for anticoagulation in pediatric patients with heparin-induced thrombocytopenia requiring extracorporeal life support.
Heparin-induced thrombocytopenia (HIT) is a well recognized and described immune phenomenon in adults. However, pediatric data on the incidence, treatment, and complications of HIT are limited. Despite the widespread use of heparin in pediatric patients and the repeated and sustained exposures to heparin in neonates and children with congenital heart disease, HIT has been infrequently recognized and under-reported in this population. HIT is an intensely procoagulant disorder and carries significant morbidity and mortality. In this case series, we describe HIT management with argatroban as alternative anticoagulation in 3 children requiring extracorporeal life support.
Potter
Katherine E
KE
Department of Pediatrics, University of Louisville, Louisville, KY 40202, USA. katherine@louisville.edu
Raj
Ashok
A
Sullivan
Janice E
JE
D000925:Anticoagulants / Q000008:administration & dosage*; D001120:Arginine / Q000031:analogs & derivatives; D005112:Extracorporeal Circulation; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010875:Pipecolic Acids / Q000008:administration & dosage*; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000401:mortality / Q000628:therapy*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010875:Pipecolic Acids; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; C031942:argatroban